Verteporfin photodynamic therapy for neovascular age-related ...

More documents

Recommendations

Info

84 References16. Stelmack J. Quality of life of low-vision patients and outcomes of low-vision rehabilitation.Optom Vis Sci 2001;78:335–42.17. Margolis MK, Coyne K, Kennedy-Martin T, Baker T, Schein O, Revicki DA. Vision-specificinstruments for the assessment of health-related quality of life and visual functioning: aliterature review. Pharmacoeconomics 2002;20:791–812.18. Brown GC, Sharma S, Brown MM, Kistler J. Utility values and age-related maculardegeneration. Arch Ophthalmol 2000;118:47–51.19. Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A. Ranibizumab and pegaptanibfor the treatment of age-related macular degeneration: a systematic review and economicevaluation. Health Technol Assess 2008;12(16).20. Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, et al. Verteporfinphotodynamic therapy cohort study: report 1: effectiveness and factors influencingoutcomes. Ophthalmology 2009;116:e1–8.21. Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, et al. Verteporfinphotodynamic therapy cohort study: report 3: cost effectiveness and lessons for futureevaluations. Ophthalmology 2009;116:2471–7.22. Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, et al. Verteporfinphotodynamic therapy cohort study: report 2: clinical measures of vision and health-relatedquality of life. Ophthalmology 2009;116:2463–70.23. Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, et al. Economic burden ofbilateral neovascular age-related macular degeneration: multi-country observational study.Pharmacoeconomics 2008;26:57–73.24. Garattini L, Castelnuovo E, Lanzetta P, Viscarra C, Ricci E, Parazzini F, et al. Direct medicalcosts of age-related macular degeneration in italian hospital ophthalmology departments. Amulticenter, prospective 1-year study. Eur J Health Econ 2004;5:22–7.25. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerlandand cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol2001;16:218–22.26. Meads C, Salas C, Roberts T, Moore D, Fry-Smith A, Hyde C. Clinical effectiveness andcost-utility of photodynamic therapy for wet age-related macular degeneration: a systematicreview and economic evaluation. Health Technol Assess 2003;7(9).27. Stirling B, Shoshanna S, Taryn S, Gold M. Has the time come for cost-effectiveness analysisin US health care? Health Econ Pol Law 2009;4:425–43.28. Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost–utility of photodynamictherapy in eyes with neovascular macular degeneration – a value-based reappraisal with5-year data. Am J Ophthalmol 2005;140:679–87.29. Gold MR, Patrick DL, Torrance GW, Fryback DG, Hadorn DC, Kamlet MS, et al. Identifyingand valuing outcomes. In Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Costeffectivenessin health and medicine. New York, NY; Oxford University Press; 1996. pp.82–134.30. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) StudyGroup. Verteporfin therapy of subfoveal choroidal neovascularization in patients with agerelated macular degeneration: additional information regarding baseline lesion composition’simpact on vision outcomes. TAP report no. 3. Arch Ophthalmol 2002;120:1443–54.31. Brown GC. Vision and quality-of-life. Trans Am Ophthalmol Soc 1999;97:473–511.
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 68532. Meads C, Hyde C. What is the cost of blindness? Br J Ophthalmol 2003;87:1201–4.33. Wright SE, Keeffe JE, Thies LS. Direct costs of blindness in australia. Clin Exp Ophthalmol2000;28:140–2.34. Hart PM, Chakravarthy U, Mackenzie G, Chisholm IH, Bird AC, Stevenson MR, et al. Visualoutcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapyfor age-related macular degeneration. Arch Ophthalmol 2002;120:1029–38.35. Ali F, Chan WC, Stevenson MR, Muldrew KA, Chakravarthy U. Morphometric analysisof angiograms of exudative lesions in age-related macular degeneration. Arch Ophthalmol2004;122:710–15.36. Hogg R, Curry E, Muldrew A, Winder J, Stevenson M, McClure M, et al. Identification oflesion components that influence visual function in age-related macular degeneration. Br JOphthalmol 2003;87:609–14.37. Verteporfin Roundtable 2000 and 2001 Participants. Treatment of age-related maculardegeneration with photodynamic therapy (TAP) study group principal investigators;Verteporfin in photodynamic therapy (VIP) study group principal investigators.Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidalneovascularization due to age-related macular degeneration and other causes. Retina2002;22:6–18.38. Early Treatment Diabetic Retinopathy Study Research Group. Early Treatment DiabeticRetinopathy Study design and baseline patient characteristics: ETDRS Report Number 7.Ophthalmology 1991;98:741–56.39. Pelli DG, Robson JG, Wilkins AJ. The design of a new letter chart for measuring contrastsensitivity. Clin Vis Sci 1988;2:187–99.40. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36):I.Conceptual framework and item selection. Med Care 1992;30:473–83.41. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In Higgins JPT, Green S,editors. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley;2008. pp. 187–242. URL: www.cochrane-handbook.org (accessed 31 August 2010).42. Stevenson MR, Hart PM, Chakravarthy U, Mackenzie G, Bird AC, Owens SL, et al. Subfovealradiotherapy study. Visual functioning and quality of life in a randomised controlled clinicaltrial SFRADS report 2. Br J Ophthalmol 2005;89:1045–51.43. Desai P, Minassian DC, Reidy A. National cataract survey 1997–8: a report of the results ofthe clinical outcomes. Br J Ophthalmol 1999;83:1336–40.44. Browne JP, Hopkins C, Slack R, Topham J, Reeves BC, Lund V, et al. Health-related quality oflife after polypectomy with and without additional surgery. Laryngoscope 2006;116:297–302.45. Langham J, Reeves BC, Lindsay KW, van der Meulen JH, Kirkpatrick PJ, Gholkar AR, et al.Variation in outcome after subarachnoid hemorrhage: a study of neurosurgical units in UKand Ireland. Stroke 2009;40:111–18.46. Maguire MG, Klein ML, Chamberlin JA. Recurrent choroidal neovascularization after argonlaser photocoagulation for neovascular maculopathy. Macular Photocoagulation StudyGroup. Arch Ophthalmol 1986;104:503–12.47. Vingerling JR, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration andsmoking. The Rotterdam Study. Arch Ophthalmol 1996;114:1193–6.48. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-relatedmacular degeneration: a review of association. Eye 2005;19:935–44.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
Page 5 and 6:
DOI: 10.3310/hta16060Health Technol
Page 12 and 13:
xExecutive summaryretreat on criter
Page 14 and 15:
xiiExecutive summaryof data, with i
Page 16 and 17:
2 Introductionon-going or new clini
Page 18 and 19:
4 Introductionof VPDT in routine cl
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31:
Page 34 and 35:
20 Key changes to the protocolThese
Page 36 and 37:
22 Key changes to the protocolCentr
Page 38 and 39:
24 Key changes to the protocolADVER
Page 40 and 41:
26 Key changes to the protocolPlan
Page 42 and 43:
28 Key changes to the protocolClass
Page 44 and 45:
30 Key changes to the protocolFor i
Page 46 and 47:
32 Key changes to the protocolIn ad
Page 48 and 49: 34 Key changes to the protocolsites
Page 52 and 53: 38 Results (1) - study cohortTABLE
Page 60 and 61: 46 Results (2) - objectives A, B, C
Page 69 and 70: DOI: 10.3310/hta16060Health Technol
Page 77: DOI: 10.3310/hta16060Health Technol
Page 80 and 81: 66 Discussion of resultsStrengths a
Page 82 and 83: 68 Discussion of resultsThe VPDT st
Page 84 and 85: 70 Discussion of resultsOur analyse
Page 86 and 87: 72 Discussion of resultsA further c
Page 88 and 89: 74 Discussion of resultsVPDT. It is
Page 95: DOI: 10.3310/hta16060Health Technol
Page 100 and 101: 86 References49. Guymer RH, Chiu AW
Page 102 and 103: 88 References83. Margrain TH. Minim
Page 104 and 105: 90 Appendix 1THE VERTEPORFIN PHOTOD
Page 106 and 107: 92 Appendix 11. Overview of Manual
Page 108 and 109: 94 Appendix 1And, if also collectin
Page 110 and 111: 96 Appendix 1more patients in the v
Page 112 and 113: 98 Appendix 12.4 Limitations of the
Page 114 and 115: 100 Appendix 1Box 2 Key advantages
Page 116 and 117: 102 Appendix 14. Study population4.
Page 118 and 119: 104 Appendix 15. Recruitment to the
Page 120 and 121: 106 Appendix 16. Background data co
Page 122 and 123: 108 Appendix 1Table 1: Schedule of
Page 124 and 125: 110 Appendix 1The Verteporfin Photo
Page 126 and 127: 112 Appendix 1• Additional clinic
Page 128 and 129: 114 Appendix 18. Recording adverse
Page 130 and 131: 116 Appendix 1level of benefit from
Page 132 and 133: 118 Appendix 1• comparison of num
Page 134 and 135: 120 Appendix 110.6 Sub-group analys
Page 136 and 137: 122 Appendix 112. Data issues12.1 D
Page 138 and 139: 124 Appendix 113. Organisation13.1
Page 140 and 141: 126 Appendix 114. References[1] Ref
Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
Page 148 and 149:
134 Appendix 1Service StructurePlea
Page 150 and 151:
136 Appendix 1Has your photographer
Page 152 and 153:
138 Appendix 1There are many differ
Page 154 and 155:
140 Appendix 1testing on vision tes
Page 156 and 157:
142 Appendix 1something to do with
Page 158 and 159:
144 Appendix 1College of Ophthalmol
Page 160 and 161:
146 Appendix 1Appendix 5:Protocol f
Page 162 and 163:
148 Appendix 16.2 Subjective Refrac
Page 164 and 165:
150 Appendix 1• The patient shoul
Page 166 and 167:
152 Appendix 1Appendix 6:Protocol f
Page 168 and 169:
154 Appendix 18. It is customary to
Page 170 and 171:
156 Appendix 1Early or Transit Phas
Page 172 and 173:
158 Appendix 1
Page 174 and 175:
160 Appendix 1---------------------
Page 176 and 177:
162 Appendix 1---------------------
Page 178 and 179:
164 Appendix 1---------------------
Page 180 and 181:
166 Appendix 1Appendix 9:Site imple
Page 182 and 183:
168 Appendix 1Option 2 - units inte
Page 184 and 185:
170 Appendix 1Dos and Don’tsDosDo
Page 186 and 187:
172 Appendix 1Resource use question
Page 188 and 189:
174 Appendix 1Appendix 11: Recommen
Page 190 and 191:
176 Appendix 1ADVERSE REACTION AND
Page 192 and 193:
178 Appendix 1acute Trust; note tha
Page 194 and 195:
180 Appendix 1Ophthalmologistrespon
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203:
Page 206 and 207:
192 Appendix 3manufacturer’s pers
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 216:
FeedbackThe HTA programme and the a
show all

Verteporfin photodynamic therapy for neovascular age-related ...

Create successful ePaper yourself

Delete template?

Save as template?